113 related articles for article (PubMed ID: 22510495)
41. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
[TBL] [Abstract][Full Text] [Related]
42. Improve efficiency and reduce bias of Cox regression models for two-stage randomization designs using auxiliary covariates.
Yang X; Zhou Y
Stat Med; 2017 May; 36(11):1683-1695. PubMed ID: 28183157
[TBL] [Abstract][Full Text] [Related]
43. The challenges of evaluating dose response in flexible-dose trials using marginal structural models.
Lipkovich I; Mallinckrodt CH; Faries DE
Pharm Stat; 2012; 11(6):485-93. PubMed ID: 23060290
[TBL] [Abstract][Full Text] [Related]
44. Assessing non-inferiority with time-to-event data via the method of non-parametric covariance.
Zhang X; Xu J; He J
Stat Methods Med Res; 2013 Jun; 22(3):346-60. PubMed ID: 21705437
[TBL] [Abstract][Full Text] [Related]
45. Adaptive design: estimation and inference with censored data in a semiparametric model.
Shen Y; Cheng Y
Biostatistics; 2007 Apr; 8(2):306-22. PubMed ID: 16787996
[TBL] [Abstract][Full Text] [Related]
46. Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.
Zhang D; Chen MH; Ibrahim JG; Boye ME; Wang P; Shen W
Stat Med; 2014 Nov; 33(27):4715-33. PubMed ID: 25044061
[TBL] [Abstract][Full Text] [Related]
47. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes.
Austin PC; Stuart EA
Stat Methods Med Res; 2017 Aug; 26(4):1654-1670. PubMed ID: 25934643
[TBL] [Abstract][Full Text] [Related]
48. Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.
Conlon AS; Taylor JM; Sargent DJ
Biometrics; 2015 Jun; 71(2):460-8. PubMed ID: 25585942
[TBL] [Abstract][Full Text] [Related]
49. Stochastic EM algorithm for doubly interval-censored data.
Dejardin D; Lesaffre E
Biostatistics; 2013 Sep; 14(4):766-78. PubMed ID: 23728851
[TBL] [Abstract][Full Text] [Related]
50. Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy.
Bai X; Liu J; Li L; Faries D
Pharm Stat; 2015; 14(6):448-54. PubMed ID: 26436533
[TBL] [Abstract][Full Text] [Related]
51. A simple, flexible, and effective covariate-adaptive treatment allocation procedure.
Loux TM
Stat Med; 2013 Sep; 32(22):3775-87. PubMed ID: 23637002
[TBL] [Abstract][Full Text] [Related]
52. Causal inference in survival analysis using pseudo-observations.
Andersen PK; Syriopoulou E; Parner ET
Stat Med; 2017 Jul; 36(17):2669-2681. PubMed ID: 28384840
[TBL] [Abstract][Full Text] [Related]
53. Inference of median difference based on the Box-Cox model in randomized clinical trials.
Maruo K; Isogawa N; Gosho M
Stat Med; 2015 May; 34(10):1634-44. PubMed ID: 25565079
[TBL] [Abstract][Full Text] [Related]
54. Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models.
Keogh RH; Gran JM; Seaman SR; Davies G; Vansteelandt S
Stat Med; 2023 Jun; 42(13):2191-2225. PubMed ID: 37086186
[TBL] [Abstract][Full Text] [Related]
55. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance.
Loeys T; Goetghebeur E
Biometrics; 2003 Mar; 59(1):100-5. PubMed ID: 12762446
[TBL] [Abstract][Full Text] [Related]
56. Landmark estimation of survival and treatment effects in observational studies.
Parast L; Griffin BA
Lifetime Data Anal; 2017 Apr; 23(2):161-182. PubMed ID: 26880366
[TBL] [Abstract][Full Text] [Related]
57. Identifiability of subgroup causal effects in randomized experiments with nonignorable missing covariates.
Ding P; Geng Z
Stat Med; 2014 Mar; 33(7):1121-33. PubMed ID: 24122906
[TBL] [Abstract][Full Text] [Related]
58. Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
Zhang M; Tsiatis AA; Davidian M; Pieper KS; Mahaffey KW
Biostatistics; 2011 Apr; 12(2):258-69. PubMed ID: 20797983
[TBL] [Abstract][Full Text] [Related]
59. Randomization-based adjustment of multiple treatment hazard ratios for covariates with missing data.
Lam D; Koch GG; Preisser JS; Saville BR; Hussey MA
J Biopharm Stat; 2017; 27(3):373-386. PubMed ID: 28281895
[TBL] [Abstract][Full Text] [Related]
60. An adjustment for a post-randomization variable in the comparison of two treatments for survival.
Heller G
Stat Med; 2001 Nov; 20(22):3475-85. PubMed ID: 11746330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
